Q-omics provides the consensus-scored FAM90A24P profile across patient tissues and cancer cell-line models. FAM90A24P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FAM90A24P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, FAM90A24P RNA expression shows 5,271 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and BRCA as cancer lineages where FAM90A24P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM90A24P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM90A24P survival associations across molecular data types. FAM90A24P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM90A24P RNA expression–survival associations across cancer types. High FAM90A24P expression shows unfavorable associations in STAD, ESCA, KICH, BLCA and OV, but favorable associations in PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FAM90A24P RNA expression.
This table summarizes FAM90A24P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM90A24P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM90A24P shows lower tumor expression in BRCA. The BRCA box plot shows higher FAM90A24P RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .019).
This table shows molecular features associated with FAM90A24P in patient tissues and cancer cell lines. In patient samples, FAM90A24P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
